End of delay leaves Teva chomping at the bit to launch fremanezumab

24 May 2018

Shareholders in and executives at Teva Pharmaceutical Industries (NYSE: TEVA) will be breathing a sigh of relief with the news that the delay to the US launch of fremanezumab will likely not be as bad as it could have been.

With Teva facing competition to its money-spinning multiple sclerosis drug Copaxone (glatiramer acetate), the investigational migraine treatment fremanezumab is seen as a key part of the company’s efforts to replace that lost revenue.

There are estimates that it could earn Teva up to $1.7 billion in annual sales by 2025, but its development hit a snag in January with the failure of the company’s partner Celltrion Healthcare (Kosdaq: 068270) to get manufacturing approval from US Food and Drug Administration (FDA).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK